logo
logo

Steelsky Ventures Invests In Raydiant Oximetry To Tackle Fetal Monitoring

Nov 18, 2021•almost 4 years ago

Description

Raydiant Oximetry Inc, a clinical-stage medical device company committed to improving health outcomes during childbirth, has received a new round of investment with participation from renowned women's health fund SteelSky Ventures. In this $5 million Series A2 funding round, SteelSky Ventures partnered with other notable venture capital funds focused on women's health, including deal lead Avestria Ventures, with participation from Rhia Ventures and FemHealth Ventures.

Company Information

Company

Raydiant Oximetry

About

The company has developed an innovative technology, LUMERAH™, a low-cost, non-invasive sensor that monitors fetal oxygenation during labor, with the aim to better identify fetal distress and reduce the rate of medically unnecessary C-sections. Raydiant Oximetry has developed the LUMERAH™, a low-cost, non-invasive sensor designed to more accurately detect fetal distress during labor and delivery. "Raydiant Oximetry is at the forefront of innovation in maternal health and their technology stands to redefine the standard of care in maternal-fetal monitoring. About Radiant Oximetry Raydiant Oximetry is a venture-backed, clinical-stage company dedicated to improving outcomes for mothers and babies during childbirth.